You are here: Industry Insights > SARS-CoV-2

News List

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2 americanpharmaceuticalreview
April 12, 2021
ImmunityBio, Inc., a clinical-stage immunotherapy company, reported initial data indicating that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the generation of ...
Study identifies possible COVID-19 drugs - including several that are FDA-approved worldpharmanews
April 08, 2021
A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other ...
Research identifies novel peptoids with potent antiviral activity against HSV-1 and SARS-CoV-2 expresspharma
April 07, 2021
Maxwell Biosciences, a preclinical stage biotechnology company developing CLAROMER brand anti-infectives, announced that the peer-reviewed, open-access journal Pharmaceuticals (MDPI) has published new scientific research findings co-authored by ...
Undetected coronavirus variant was in at least 15 countries before its discovery worldpharmanews
April 07, 2021
A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first ...
AbCellera reports bamlanivimab’s potency against SARS-CoV-2 in study pharmaceutical-technology
April 06, 2021
AbCellera (ABCL) has reported that bamlanivimab (LY-CoV555) demonstrated high potency in neutralising SARS-CoV-2 by uniquely binding both up and down confirmations of the spike receptor-binding domain (RBD) in preclinical study.
Research identifies nine potential new COVID-19 treatments expresspharma
April 06, 2021
Three already have FDA approval — the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin.
B.1.1.7 variant of COVID-19 spreading rapidly in United States worldpharmanews
April 02, 2021
The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from ...
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002 prnasia
April 02, 2021
On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
Anti-inflammatory drug protects against lethal inflammation from COVID-19 in animal models worldpharmanews
April 01, 2021
Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19.
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T prnasia
March 31, 2021
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page